GlassScriptPhysician profile
Jorge Roman
NPI 1851824825
$6,537.12
in general payments reported to CMS, 2019-2025
30 companies · $2,493 in 2025
The $2,493 reported for 2025 was more than what 81% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $283 · 2023: $1,426 · 2024: $2,335 · 2025: $2,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,174 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,173.79 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $846.17 | 2023-2025 | Ilumya, Blu-U, Odomzo |
| Genzyme Corporation | $708.96 | 2023-2025 | |
| Abbvie INC. | $705.72 | 2023-2025 | Rinvoq, Botox, Skyrizi |
| Pfizer INC. | $561.47 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $552.57 | 2022-2025 | Dupixent, Libtayo |
| Leo Pharma INC. | $409.48 | 2023-2025 | Adbry, Anzupgo |
| Incyte Corporation | $339.66 | 2023-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $335.61 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $321.73 | 2024-2025 | Zoryve |
| Galderma Laboratories, L.P. | $321.31 | 2023-2025 | Nemluvio, Aklief |
| Lilly USA, LLC | $289.17 | 2023-2024 | Olumiant, Taltz, Ebglyss |
| Novartis Pharmaceuticals Corporation | $235.72 | 2023-2025 | |
| Inari Medical, INC. | $163.21 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Amgen INC. | $154.69 | 2022-2025 | Otezla, Otezla |
| Ucb, INC. | $139.22 | 2025 | Bimzelx |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $79.99 | 2025 | |
| Mayne Pharma Commercial LLC | $55.39 | 2023-2025 | |
| Argon Medical Devices, INC. | $41.62 | 2024-2025 | Clot Management, Clot Management |
| Fidia Pharma USA INC. | $40.35 | 2025 | |
| Merck Sharp & Dohme LLC | $33.02 | 2023 | Keytruda |
| Organon LLC | $32.05 | 2025 | Vtama |
| Botanix Sb INC | $28.22 | 2025 | Sofdra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.31 | 2023 | Spevigo |
| Journey Medical Corporation | $22.14 | 2025 | |
| Lnhc, INC | $18.87 | 2025 | Zelsuvmi |
| Verrica Pharmaceuticals INC. | $17.40 | 2024 | Ycanth |
| Kerecis Limited | $15.82 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Dermavant Sciences, INC. | $15.61 | 2024 | Vtama |
| Biofrontera INC. | $14.07 | 2025 | Ameluz |
| Tempus Ai, INC | $13.57 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Roman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.